Tag: Diisopropylaminoethyl pyrrolidinone racetam

Pramiracetam (CI-879; N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide; CAS 68497-62-1; molecular formula C14H27N3O2; molecular weight 269.39 g/mol) is a second-generation nootropic of the racetam class, synthesized at Parke-Davis in the late 1970s as a structural analog of piracetam. The compound differs from piracetam by replacement of the primary amide group with a diisopropylaminoethyl amide, a modification that substantially increases lipophilicity, central nervous system penetration, and effective potency, permitting therapeutic doses approximately five to ten times lower than equivalent piracetam regimens. Pramiracetam was advanced through preclinical and clinical development at Parke-Davis (then a division of Warner-Lambert, subsequently acquired by Pfizer) with the development code CI-879. The compound was licensed to Menarini for European development and was marketed under the trade names Pramistar, Neupramir, and Remen in Italy, Belgium, and several Eastern European jurisdictions for the treatment of memory and attention deficits in aging populations with neurodegenerative and vascular dementias. The Italian marketing authorization under Menarini was maintained until 2020, when it was voluntarily withdrawn by the manufacturer. The principal pharmacological mechanism of pramiracetam, characterized in the Pugsley et al. (1983) and subsequent studies, is selective enhancement of high-affinity choline uptake (HACU) in hippocampal and cortical cholinergic nerve terminals [1]. HACU is the rate-limiting step in acetylcholine biosynthesis; pramiracetam increases the velocity of choline transport into presynaptic cholinergic neurons without altering monoamine neurotransmitter concentrations, receptor binding profiles at dopaminergic, serotonergic, adrenergic, or histaminergic sites, or monoamine oxidase activity. The selectivity of the HACU mechanism distinguishes pramiracetam from piracetam, which acts predominantly through AMPA receptor positive allosteric modulation and membrane fluidity enhancement. Additional preclinical findings include increased nitric oxide synthase activity in rat cerebral cortex following systemic administration [2] and normalization of age-related electroencephalographic abnormalities in aged Fischer-344 rats [3]. The compound does not exhibit direct cholinesterase inhibition, muscarinic or nicotinic receptor agonism, or GABAergic activity at pharmacologically relevant concentrations. Pharmacokinetics in healthy human volunteers are characterized by rapid oral absorption, with peak plasma concentrations attained in approximately two to three hours; a plasma elimination half-life of 4.5 to 6.5 hours; linear dose-proportional exposure across the studied dose range (400 to 1600 mg); negligible plasma protein binding; and predominantly renal excretion of unchanged drug with minimal hepatic metabolism [4, 5]. The absence of significant cytochrome P450 involvement reduces drug-drug interaction liability relative to hepatically metabolized nootropic and cholinergic agents. The clinical evidence base includes a two-phase placebo-controlled trial in probable Alzheimer disease conducted at the National Institutes of Neurological Disorders and Stroke (Claus et al., 1991), which found that doses up to 4000 mg daily were unlikely to confer symptomatic benefit in moderate-to-severe Alzheimer disease [6]; a placebo-controlled study of scopolamine-induced amnesia in healthy volunteers demonstrating partial reversal of anticholinergic memory impairment in both young and elderly subjects [7]; a small open-label study in traumatic brain injury rehabilitation showing improved cognitive recovery [8]; and the European registration trials conducted by Menarini supporting the indication for memory and attention deficits in elderly patients with neurodegenerative and vascular dementias. Effect sizes across these studies are consistently small to moderate, and the compound has not produced a positive Phase 3 registration-quality readout in Alzheimer disease. Pramiracetam is not approved by the United States Food and Drug Administration and is classified as an unapproved new drug in the United States. It is available as a research-grade chemical from multiple suppliers. This monograph documents the chemistry, synthesis, and structural pharmacology of pramiracetam; the high-affinity choline uptake mechanism and supporting preclinical pharmacology; the comprehensive human pharmacokinetic record; the clinical evidence base across cognitive indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications for research use; adverse-event signal; and a structured comparative assessment of five racetam-class and cholinergic nootropic compounds against pramiracetam on five competency standards.